Clinical trial

Gene Expression Profiling in PBMCs as a Tool for Prediction of Infliximab Responsiveness in Rheumatoid Arthritis

NCT00213564

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention response to infliximab associated with methotrexate Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Gene Expression Profiling in PBMCs as a Tool for Prediction of Infliximab Responsiveness in Rheumatoid Arthritis

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2003-04-01

PhaseN/A

Conditions

Rheumatoid Arthritisverified · MONDO: rheumatoid arthritis

Interventions

response to infliximab associated with methotrexateDRUG

Sponsors & collaborators

University Hospital, Rouenlead sponsor

Mapped research locations

RouenFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00213564 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.